Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Current Size And Growth Outlook For The Chickenpox Vaccine Market?

In the past few years, there has been a robust expansion in the market size of the chickenpox vaccine. The market is set to progress from a value of $3.57 billion in 2024 up to $3.76 billion in 2025, with the compound annual growth rate (CAGR) being 5.5%. Factors such as vaccine development, regulatory endorsements, disease prevalence, vaccination policies, and public health programs account for this historical growth.

The market size for the chickenpox vaccine is predicted to witness a robust expansion in the upcoming years, reaching “$4.82 billion by 2029 with a compound annual growth rate (CAGR) of 6.4%. The escalating growth within the prediction period can be credited to factors such as confidence and acceptance in the public view, readiness for pandemics, research, development, and the rising demand in emerging markets, along with the advancement in healthcare infrastructures. The forthcoming period will also spotlight major trends like educational campaigns regarding the vaccine, the monitoring of negative events, strategies in vaccine pricing, pioneering innovations, and the deployment of artificial intelligence.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8581&type=smp

What Drivers Are Accelerating Expansion Of The Chickenpox Vaccine Market?

The increasing incidence of chickenpox is anticipated to drive the expansion of the chickenpox vaccine market. Chickenpox is a severe infectious ailment triggered by the varicella-zoster virus (VZV), which results in an itchy, fluid-filled rash. The rise in chickenpox cases necessitates an increase in varicella vaccine immunization, subsequently boosting the demand for chickenpox vaccines. As per a report by the National Library of Medicine (NLM), a US-based biomedical library, in October 2023, a study of GP consultations for chickenpox from September 2016 to December 2022 observed an average weekly rate of 3.4 per 100,000 individuals in England, with frequent peaks in weeks 13 to 15 yearly. While the usual epidemic peaks were not present during the COVID-19 pandemic owing to social distancing and lockdowns, consultation rates in 2022 were higher among children under 1 year old compared to the years before the pandemic, suggesting altered transmission patterns. Consequently, the increasing incidence of chickenpox is stimulating the expansion of the chickenpox vaccine market.

What Are The Main Segment Classifications In The Chickenpox Vaccine Market?

The chickenpox vaccine market covered in this report is segmented –

1) By Vaccine: Monovalent Varicella Vaccine, Combination Varicella Vaccine

2) By Application: Mumps, Measles, Rubella, And Varicella Immunization, Herpes Zoster Immunization, Chickenpox Vaccination

3) By End-Users: Hospitals, Clinics, Other End-Users

Subsegments:

1) By Monovalent Varicella Vaccine: Live Attenuated Varicella Vaccine

2) By Combination Varicella Vaccine: Measles, Mumps, Rubella, And Varicella (MMRV) Vaccine

How Are Industry Trends Steering The Expansion Of The Chickenpox Vaccine Market?

The growing trend in the chickenpox vaccine market is the development of new drugs by leading companies. These companies are creating innovative drugs with increased effectiveness and unique derivatives in order to maintain their status in the field. One example is Sinovac Biotech Ltd., a China-based firm specialising in vaccine research, development, and production, which announced in November 2022 that it had been given prequalification by the World Health Organization (WHO) for its live attenuated chickenpox (varicella) vaccine. This is the first varicella vaccine in the world to be prequalified. The vaccine, derived from the Oka strain, is produced in SINOVAC’s unique Human Diploid Cell (SV-1 strain). This cell is formed by cultivating, harvesting the virus, adding stabilisers and then freeze-drying. In a phase III efficacy trial, the seroconversion rate for the group of children aged 1 to 12 who were given the vaccine was 97.1%; the vaccine’s efficacy in protecting against chickenpox and breakthrough chickenpox was 87.1% and 89.2%, respectively. The vaccine also provided complete protection against both mild and severe cases.

Which Firms Are Driving Innovation Within The Chickenpox Vaccine Market?

Major companies operating in the chickenpox vaccine market include Merck & Co., Sanofi Pasteur, Takeda Pharmaceutical Company Limited, CSL Limited, Pfizer Inc., Seqirus, Serum Institute of India Pvt. Ltd., Bharat Biotech, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co., Ltd., Chongqing Zhifei Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., Adimmune Corporation, Biological E. Limited, Walvax Biotechnology Co., Ltd., Zydus Cadila, Indian Immunologicals Ltd., Panacea Biotec Ltd., Bio Farma, PT Kalbe Farma Tbk, CanSino Biologics

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/chickenpox-vaccine-global-market-report

What Are The Emerging Regional Trends Driving The Chickenpox Vaccine Market?

North America was the largest region in the chickenpox vaccine market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chickenpox vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=8581&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model